Quercetin pretreatment (100 mg/kg, orally) was found to reduce airway cholinergic responses, lung inflammation, and epidermal accumulation as well as CD8+ T cells, CD11b+/CD11c+ macrophages, and neutrophils in rhinovirus-induced COPD phenotype mice. This evidence concerns the gene ITGAX and chronic obstructive pulmonary disease.